Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance
Authors:
- 1 September 2015
- journal article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 227 (2) , 71-81
Abstract
Antipsychotics (APs) are linked to diabetes, even without weight gain. Whether anti-diabetic drugs are efficacious in reversing the direct effects of APs on glucose pathways is largely undetermined. We tested two metformin (Met) doses to prevent impairments seen following a dose of olanzapine (Ola) (3 mg/kg); glucokinetics were measured using the hyperinsulinemic-euglycemic clamp (HIEC). Met (150 mg/kg;n=13, or 400 mg/kg;n=11) or vehicle (Veh) (n=11) was administered through gavage preceding an overnight fast, followed by a second dose prior to the HIEC. Eleven additional animals were gavaged with Veh and received a Veh injection during the HIEC (Veh/Veh); all others received Ola. Basal glucose was similar across treatment groups. The Met 400 group had significantly greater glucose appearance (Ra) in the basal period (i.e., before Ola, or hyperinsulinemia) vs other groups. During hyperinsulinemia, glucose infusion rate (GINF) to maintain euglycemia (reflective of whole-body insulin sensitivity) was higher in Veh/Veh vs other groups. Met 150/Ola animals demonstrated increased GINF relative to Veh/Ola during early time points of the HIEC. Glucose utilization during hyperinsulinemia, relative to basal conditions, was significantly higher in Veh/Veh vs other groups. The change in hepatic glucose production (HGP) from basal to hyperinsulinemia demonstrated significantly greater decreases in Veh/Veh and Met 150/Ola groups vs Veh/Ola. Given the increase in basal Rawith Met 400, we measured serum lactate (substrate for HGP), finding increased levels in Met 400 vs Veh and Met 150. In conclusion, Met attenuates hepatic insulin resistance observed with acute Ola administration, but fails to improve peripheral insulin resistance. Use of supra-therapeutic doses of Met may mask metabolic benefits by increasing lactate.Keywords
This publication has 66 references indexed in Scilit:
- Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female ratsJournal of Psychiatry and Neuroscience, 2012
- A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy VolunteersPLOS ONE, 2011
- Does long-term metformin treatment increase cardiac lipoprotein lipase?Metabolism, 2011
- Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysisMolecular Psychiatry, 2010
- Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal modelSchizophrenia Research, 2009
- The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intoleranceSchizophrenia Research, 2008
- Increased lactate levels and reduced pH in postmortem brains of schizophrenics: Medication confoundsJournal of Neuroscience Methods, 2008
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJournal of Clinical Investigation, 2007
- Antipsychotic induced metabolic abnormalities: An interaction study with various PPAR modulators in miceLife Sciences, 2006
- Extent and Management of Cardiovascular Risk Factors in Patients With Type 2 Diabetes and Serious Mental IllnessJournal of Nervous & Mental Disease, 2006